The Hidden Link Between HIV and Cardiomyopathy: Unraveling HIV’s Impact on the Heart

For years, human immunodeficiency virus (HIV) was considered primarily an immunological threat. However, advances in HIV treatment have dramatically increased life expectancy for those living with the virus, revealing a growing incidence of long-term cardiovascular complications, particularly cardiomyopathy. This review explores the complex relationship between HIV and cardiomyopathy, examining the underlying mechanisms, clinical presentations, diagnostic approaches, and current treatment strategies.

Understanding HIV-Associated Cardiomyopathy

Cardiomyopathy, a disease of the heart muscle, can manifest in various forms, impacting the heart’s ability to pump blood effectively. In individuals with HIV, the prevalence of cardiac involvement has been reported to range from 28% to 73% ¹. The development of HIV-associated cardiomyopathy is a multifaceted process, influenced by both direct and indirect effects of the virus.

Pathogenesis: How HIV Impacts the Heart

The pathogenesis of HIV-associated cardiomyopathy is complex and not fully understood, but research has deepened our understanding of the underlying mechanisms ². Several factors contribute to its development:

• Direct Viral Infection: HIV can directly infect cardiac cells, leading to inflammation and damage.
• Chronic Inflammation: HIV triggers chronic immune activation and inflammation, even with antiretroviral therapy, contributing to cardiovascular dysfunction.
• Co-morbidities: Individuals with HIV often have co-existing conditions like hypertension, diabetes, and kidney disease, which independently increase the risk of cardiomyopathy.
• Antiretroviral Therapy (ART): While life-saving, some ART medications have been linked to cardiac side effects, though newer regimens are generally better tolerated.

Clinical Manifestations

HIV-associated cardiomyopathy can present with a range of symptoms, often mirroring those of other forms of cardiomyopathy. These can include:

• Shortness of breath
• Fatigue
• Swelling in the ankles, feet, and legs
• Irregular heartbeat
• Chest pain

However, symptoms can be subtle or attributed to other conditions, leading to delayed diagnosis.

Diagnosis of HIV-Associated Cardiomyopathy

Diagnosing HIV-associated cardiomyopathy requires a comprehensive evaluation. Advances in cardiac imaging modalities are crucial for accurate assessment ². Diagnostic tools include:

• Echocardiogram: Provides images of the heart’s structure and function.
• Electrocardiogram (ECG): Records the heart’s electrical activity.
• Cardiac Magnetic Resonance Imaging (MRI): Offers detailed images of the heart muscle and can detect inflammation and scarring.
• Cardiac Biomarkers: Blood tests to measure substances released by damaged heart muscle.

Treatment Strategies

Management of HIV-associated cardiomyopathy involves a multi-pronged approach:

• Antiretroviral Therapy (ART): Effective viral suppression is paramount to reduce inflammation and slow disease progression.
• Management of Co-morbidities: Aggressive control of hypertension, diabetes, and other cardiovascular risk factors is essential.
• Heart Failure Medications: Standard heart failure therapies, such as ACE inhibitors, beta-blockers, and diuretics, may be used to manage symptoms and improve heart function.
• Lifestyle Modifications: Adopting a heart-healthy lifestyle, including a balanced diet, regular exercise, and smoking cessation, is crucial.

The Evolving Landscape of HIV and Cardiovascular Health

As individuals with HIV live longer, the incidence of cardiovascular disease, including cardiomyopathy, is expected to rise ⁴. Continued research is vital to further elucidate the mechanisms underlying HIV-associated cardiomyopathy and to develop targeted therapies. This review highlights the importance of recognizing and addressing this emerging cardiovascular threat in the HIV-positive population ³.